Journey Medical Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

6 Months Ended

Jun. 30, 2022

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

Schedule of disaggregation of net revenues

The Company’s net product revenues are summarized as follows:


		Three-Month Periods Ended						Six-Month Periods Ended
		June 30,						June 30,
($ in thousands)		2022			2021			2022			2021
Qbrexza^®		$	6,111		$	4,568		$	13,487		$	4,568
Accutane^®			5,200			1,945			10,107			2,141
Amzeeq			1,265			—			4,731			—
Targadox^®			2,756			5,727			5,390			12,926
Ximino^®			1,035			1,312			2,002			3,413
Zilxi			555			—			1,297			—
Exelderm^®			1,313			1,736			2,017			2,953
Other branded revenue			—			—			—			6
Total product revenues		$	18,235		$	15,288		$	39,031		$	26,007

Schedule of other revenue


		Three-Month Periods Ended						Three-Month Periods Ended
		June 30,						June 30,
($ in thousands)		2022			2021			2022			2021
Other revenue			56			—			2,556			—
Total other revenue		$	56		$	—		$	2,556		$	—